Market capitalization | $12.13b |
Enterprise Value | $11.39b |
P/E (TTM) P/E ratio | 36.30 |
EV/FCF (TTM) EV/FCF | 23.02 |
EV/Sales (TTM) EV/Sales | 5.37 |
P/S ratio (TTM) P/S ratio | 5.73 |
P/B ratio (TTM) P/B ratio | 4.83 |
Revenue growth (TTM) Revenue growth | 26.69% |
Revenue (TTM) Revenue | $2.12b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:
28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,120 2,120 |
27%
27%
|
|
Gross Profit | 2,062 2,062 |
27%
27%
|
|
EBITDA | 569 569 |
81%
81%
|
EBIT (Operating Income) EBIT | 545 545 |
84%
84%
|
Net Profit | 339 339 |
92%
92%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kevin Gorman |
Employees | 1,400 |
Founded | 1992 |
Website | www.neurocrine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.